<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903043</url>
  </required_header>
  <id_info>
    <org_study_id>MIR-20895</org_study_id>
    <nct_id>NCT02903043</nct_id>
  </id_info>
  <brief_title>Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With COPD</brief_title>
  <official_title>Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation J-D Bégin de l'Université Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limb muscle dysfunction, characterized by loss of capillaries, is amongst the most
      troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to
      poor functional status and premature mortality.

      One prevailing hypothesis stipulates that modification in the expression of miR-204 leads to
      change the regulation of angiogenesis in vastus lateralis of patients with COPD when compared
      to controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators objective is to investigate the impact of COPD on key signaling pathways
      involved in the muscle angiogenesis. Mild to severe COPD patients and healthy controls will
      be recruited. All of the investigators patients will undergo a thorough baseline assessment
      in pulmonary capacity and body composition. Blood sampling and biopsy of the quadriceps will
      be done. Key proteins and microRNAs of signaling intramuscular pathways involved in
      angiogenesis will be measured in the quadriceps.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>miR-204 in limb muscles in patients with COPD</measure>
    <time_frame>At baseline (COPD patients in a stable state of the disease)</time_frame>
    <description>i)To measure miR-204 level in the quadriceps of patients with COPD in comparison to controls.
ii) To study possible involvement of miR-204 on pathways regulating angiogenesis and on muscle microcirculation in these individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>microRNAs in limb muscles of patients with COPD</measure>
    <time_frame>At baseline (COPD patients in a stable state of the disease)</time_frame>
    <description>i) To measure microRNAs levels in the quadriceps of patients with COPD in comparison to controls.
ii) To study possible involvement of these microRNAs on pathways regulating myogenesis, angiogenesis and on muscle microcirculation in these individuals.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <description>Quadriceps biopsies will be done. No drug administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Quadriceps biopsies will be done. No drug administration.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample ad muscle biopsy of vastus lateralis (quadriceps)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD (FEV1/FVC &lt; 0.70)

          -  Healthy subjects: no evidence of airways obstruction (FEV1/FVC &gt; 0.70 and FEV1 &gt; 0.80
             predicted)

          -  Smoking history &gt; 10 pack-years

          -  Ex-smoker &gt;6 months

        Exclusion Criteria:

          -  Chronic hypoxemia and/or hypercapnia (PaO2 &lt; 60 mmHg or SpO2 &lt; 88% at rest and/or
             PaCO2 &gt; 45 mmHg)

          -  Recent exacerbation or oral corticosteroids (&lt; 2 months)

          -  Recent cancer (&lt; 3 years)

          -  Diabetes

          -  Myopathy, neuromuscular, neurological or articular diseases

          -  Kidney disease

          -  Other respiratory diseases

          -  Unstable cardiac disease

          -  Physical activity score &gt; 9 in the Voorips questionnaire

          -  BMI &gt; 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Maltais, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Annie Dubé</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>MicroRNAs</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Skeletal muscle</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

